AKYNZEO
Total Payments
$2.2M
Transactions
3,662
Doctors
2,039
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $441.74 | 23 | 23 |
| 2023 | $6,085 | 103 | 76 |
| 2022 | $130,016 | 119 | 94 |
| 2021 | $239,324 | 108 | 91 |
| 2020 | $188,954 | 14 | 8 |
| 2019 | $327,370 | 1,222 | 887 |
| 2018 | $297,723 | 1,117 | 803 |
| 2017 | $1.0M | 956 | 692 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 41 | 76.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $223,420 | 64 | 10.1% |
| Travel and Lodging | $122,002 | 119 | 5.5% |
| Consulting Fee | $63,203 | 17 | 2.9% |
| Food and Beverage | $61,105 | 3,289 | 2.8% |
| Space rental or facility fees (teaching hospital only) | $37,659 | 25 | 1.7% |
| Education | $1,577 | 107 | 0.1% |
Payments by Type
Research
$1.7M
41 transactions
General
$508,966
3,621 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A single arm study to evaluate if anamorelin can help decrease cancer-related fatigue in patients with advanced cancer. | Helsinn Healthcare SA | $689,749 | 0 |
| Treatment of Refractory Nausea | Helsinn Therapeutics (U.S.), Inc. | $472,355 | 0 |
| Prevention of CINV in patients receiving MEC/HEC who experienced breakthrough after one cycle of chemotherapy | Helsinn Therapeutics (U.S.), Inc. | $255,375 | 0 |
| Trial of NEPA for Prevention of CINV in Patients receiving the BEAM | Helsinn Therapeutics (U.S.), Inc. | $104,032 | 0 |
| Trial of NEPA for Prevention of CINV in Patients receiving BEAM | Helsinn Therapeutics (U.S.), Inc. | $89,101 | 0 |
| Trial for NEPA for Prevention of CINV in Patients receiving BEAM | Helsinn Therapeutics (U.S.), Inc. | $46,504 | 0 |
| Evaluating the Efficacy of Akynzeo in the management of CINV in patients treated for advanced stage ovarian carcinoma | Helsinn Therapeutics (U.S.), Inc. | $19,635 | 0 |
| Single-Center, Single-Arm, Open-Label feasibility study | Helsinn Therapeutics (U.S.), Inc. | $18,963 | 0 |
Top Doctors Receiving Payments for AKYNZEO — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Fairfield, CT | $180.43 | 10 |
| , M.D | Gynecologic Oncology | Torrance, CA | $154.55 | 8 |
| , MD | Hematology & Oncology | Flushing, NY | $146.18 | 8 |
| , MD | Internal Medicine | Huntersville, NC | $145.48 | 3 |
| , DO | Gynecologic Oncology | Littleton, CO | $142.30 | 2 |
| , MD | Hematology & Oncology | San Antonio, TX | $141.80 | 8 |
| , MD | Hematology & Oncology | Brockton, MA | $139.79 | 8 |
| , M.D | Hematology & Oncology | Honolulu, HI | $139.45 | 1 |
| , MD | Hematology | Honolulu, HI | $139.45 | 1 |
| , M.D | Hematology & Oncology | Honolulu, HI | $139.45 | 1 |
| , M.D | Medical Oncology | Honolulu, HI | $139.45 | 1 |
| , M.D | Hematology & Oncology | Honolulu, HI | $139.45 | 1 |
| , M.D | Specialist | Canton, OH | $137.67 | 4 |
| , M.D | Hematology & Oncology | Rockledge, FL | $134.50 | 2 |
| , M.D | Hematology & Oncology | San Antonio, TX | $133.11 | 8 |
| , MD | Hematology & Oncology | Coos Bay, OR | $130.52 | 6 |
| , M.D | Internal Medicine | Fairfield, CT | $128.27 | 7 |
| , MD | Hematology & Oncology | San Juan, PR | $126.75 | 6 |
| , M.D | Internal Medicine | Goshen, NY | $125.00 | 1 |
| , M.D | Hematology & Oncology | Jackson, MS | $125.00 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $125.00 | 1 |
| , M.D | Radiation Oncology | Jackson, MS | $125.00 | 1 |
| , M.D | Radiation Oncology | Webster, TX | $125.00 | 1 |
| Robert Kirby | — | Plano, TX | $124.99 | 1 |
| , M.D | Nuclear Radiology | Stony Brook, NY | $124.96 | 1 |
Ad
Manufacturing Companies
- Helsinn Therapeutics (U.S.), Inc. $1.3M
- Helsinn Healthcare SA $874,552
- Verity Pharmaceuticals Inc. $2,781
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 2,039
- Transactions 3,662
About AKYNZEO
AKYNZEO is a drug associated with $2.2M in payments to 2,039 healthcare providers, recorded across 3,662 transactions in the CMS Open Payments database. The primary manufacturer is Helsinn Therapeutics (U.S.), Inc..
Payment data is available from 2017 to 2024. In 2024, $441.74 was paid across 23 transactions to 23 doctors.
The most common payment nature for AKYNZEO is "Unspecified" ($1.7M, 76.9% of total).
AKYNZEO is associated with 8 research studies, including "A single arm study to evaluate if anamorelin can help decrease cancer-related fatigue in patients with advanced cancer." ($689,749).